TriangleNCT00459862 · OUTCOME
Progression-free Survival Assessed by RECIST
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From study enrollment to the first date of disease progression or death as a result of any cause, whichever occurs first, up to 3 years
Analysis population: All 34 participants were analyzed for this endpoint.
Groups in this outcome
Arm I
Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Arm I | 34 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm I | 4.2 | Not reported | 2.5 | 5.9 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.5
- upper Limit
- 5.9
- value
- 4.2
- denoms
- counts
- group Id
- OG000
- value
- 34
- units
- Participants
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Arm I
- param Type
- MEDIAN
- population Description
- All 34 participants were analyzed for this endpoint.
- reporting Status
- POSTED
- time Frame
- From study enrollment to the first date of disease progression or death as a result of any cause, whichever occurs first, up to 3 years
- title
- Progression-free Survival Assessed by RECIST
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice